SUNGLASSES - Tough, Durable, and Cool...
It's the Sunglass Choice of the Stars...
Normal: $39.99 DEAL: $3.99
http://pd.gophercentral.com/r/186/a/3321/l/xr7ry5
------------------------------------------------------------
You can discuss this issue or any other topic in the new
Health Tips forum. Check it out here...


Health Tips Archives & Forum
------------------------------------------------------------
Friday, May 28th, 2010

Scientists identify a new cancer gene

LONDON - British and U.S. scientists say they've identified
a new cancer gene that could lead to more effective treat-
ments for pediatric glioma. Researchers said their discovery
was one of a number of significant genetic differences found
between the adult and youth form of the disease. Gliomas are
the most common form of brain tumor. Clinicians and scien-
tists at The U.K. Institute of Cancer Research, the Univer-
sity of Nottingham, the U.K. Children's Cancer and Leukemia
Group and the St Jude Children's Research Hospital in the
United States said they conducted the most comprehensive
analysis to date of pediatric high-grade glioma, making a
detailed scan of the genome of 78 newly-diagnosed patients,
comparing pediatric tumor samples with the genome of adult
gliomas. "We found significant differences between the
genomes of adult and young people's gliomas," said Dr. -
Chris Jones of the IRC. "This is an important finding
because it means studies on adult gliomas cannot simply be
applied to younger patients, and it has particular implica-
tions for drug trials." The discovery is reported in the
Journal of Clinical Oncology.


FDA OKs H1N1 influenza virus test

WASHINGTON - The U.S. Food and Drug Administration announced
approval Monday of the Simplexa Influenza A H1N1 (2009) virus
test. Until Monday's clearance, tests for 2009 H1N1 virus
were only available through an Emergency Use Authorization,
which allows the FDA to authorize the use of unapproved or
uncleared medical products during the time a declaration of
emergency is in effect. On April 26, 2009, the U.S. Depart-
ment of Health and Human Services declared a public health
emergency due to the 2009 H1N1 Influenza Virus. "With this
clearance, the availability of Simplexa H1N1 test will not
be affected when the public health emergency expires," said
Dr. Jeffrey Shuren, director of the FDA's Center for Devices
and Radiological Health. Using specimens from nasal swabs or
nasal aspirates, the Simplexa Influenza A H1N1 test simultan-
eously amplifies and detects two regions of the influenza
virus genome and an internal control in patients showing
signs and symptoms of respiratory infection, the FDA said.
A positive result indicates a patient is infected with the
virus, but the test does not indicate the stage of infection.
A negative result does not preclude influenza virus infection.
The test is manufactured by Focus Diagnostics Inc. of
Cypress, Calif.

------------------------------------------------------------
Neck Genie Elite
No pain... No expensive surgery...

Normal Price: $19.99
DEAL PRICE: $9.99
Get two for $15.98

The Neck Genie will give your face a lift resulting in tighter
and firmer skin. It eliminates sagging skin and can reduce a
double-chin or neck folds. It does for your neckline what
exercise does for your body, making you look and feel younger.
Take years off your appearance and gently firm the underlying
muscles of the neck and tighten the skin without expensive
plastic surgery.

Use just two minutes a day and the Neck Genie will help you
tighten and tone your neck, chin and face the quick, easy,
pain-free way. Redefine your profile and reduce facial
sagging. The secret is in its new and improved version that
has a built-in a-d-j-u-s-t-a-b-l-e tension mechanism that
gently firms the underlying muscles of the neck and tighten
skin at the same time for a dramatic lift. No pain - No
expensive surgery.

Get one for $9.99 or buddy up with a friend and get two for $15.98 =

http://pd.gophercentral.com/u/1072/c/120/a/3321
------------------------------------------------------------

Ebola vaccine found better than thought

BETHESDA, Md. - U.S. scientists say an experimental Ebola
vaccine protects monkeys against not only the two most lethal
Ebola virus species, but also a new Ebola virus. The vac-
cine, developed at the National Institutes of Health, was
originally designed to protect against two Ebola viruses
discovered in 1976. But now researchers have discovered it
also protects against a newer Ebola virus species that was
identified in 2007. The medical investigators, led by Nancy
Sullivan of the Vaccine Research Center at the National
Institute of Allergy and Infectious Diseases, included sci-
entists from the U.S. Army Medical Research Institute for
Infectious Diseases and the Centers for Disease Control and
Prevention. "The important work by Dr. Sullivan and her
colleagues shows that it is possible to generate immunity
to newly identified species of Ebola virus with a vaccine
originally designed to protect against a different species,"
NIAID Director Dr. Anthony Fauci said. "This finding will
guide future vaccine design and may open an avenue for
developing a single vaccine that works against both known
and emerging Ebola virus species." The research is reported
in the journal PLoS Pathogens.


Gene pattern may aid in kidney transplants

BETHESDA, Md. - U.S. scientists have identified a gene pat-
tern among kidney transplant recipients who haven't rejected
their kidneys, despite stopping anti-rejection drugs. The
researchers said the finding might help identify other trans-
plant recipients who could safely reduce or end use of im-
munosuppressive therapy. The research from the Immune
Tolerance Network, an international research consortium,
included three lead investigators: Dr. Kenneth Newell of
Emory University, Dr. Laurence Turka of Beth Israel Deaconess
Medical Center and Harvard Medical School in Boston and Vicki
Seyfert-Margolis of the U.S. Food and Drug Administration.
"The immunosuppressive therapy regimens that organ transplant
recipients must endure have toxic side effects and increase
the recipients' vulnerability to infections and cancer," said
Dr. Antony Fauci, director of the National Institute of
Allergy and Infectious Disease, which supported the research.
"This study holds promise for identifying kidney transplant
recipients who might be able to minimize or withdraw from
their use of anti-rejection drugs. However, large, prospec-
tive studies will be necessary to determine if the same bio-
markers identified in the current study are reliable predic-
tors of immune tolerance." The findings appear in the early
online edition of the Journal of Clinical Investigation.

------------------------------------------------------------
You won't find a more effective product...
SAVEX FOOT CARE SALVE

List Price: $9.99
DEAL PRICE: $3.49
Get Two for $5.98

Feel the soothing sweetness of this salve working its magic
on your tired, dry or itchy feet.

Featuring skin-friendly oils like Mineral, Lanolin and more
(full list on site), this deep-penetrating foot salve will
re-hydrate severely dry skin, aid in the healing of cracks and
eliminate itching. This wonder salve even prevents foot odor!

Unlike lotions which are high in water content which can
actually cause dryness, this salve has no water to promote
faster healing... for healthier feet. Also contains Menthol
which acts as an antiseptic, anti-irritant & cooling skin soother.

The Savex Foot Care Salve is a MUST for any diabetic.

It lasts long too... it can provide hydration for up to six
hours... no more constant applying of lotions.

You won't find a more effective product as Savex Foot Care
Salve. Grab a jar for $3.49 or get two for $5.98. VISIT:
http://pd.gophercentral.com/u/14469/c/120/a/3321
------------------------------------------------------------

New treatment for Pompe disease approved

WASHINGTON - The U.S. Food and Drug Administration announced
approval Tuesday of a new treatment for some patients with
late-onset (non-infantile) Pompe disease. The FDA said the
rare genetic disorder produces heart and skeletal muscle
weakness that progresses to respiratory failure. The federal
agency said it approved Lumizyme (alglucosidase alfa) for
patients ages 8 years and older with the disease in which a
gene mutation prevents the body from making an enzyme, or
making enough of the enzyme (acid alpha-glucosidase) for
proper muscle functioning. Lumizyme is believed to work by
replacing the deficient enzyme, thereby reducing the accumu-
lated glycogen in heart and skeletal muscle cells, officials
said. The FDA said Lumizyme will carry a Boxed Warning be-
cause of the risk of severe allergic and immune-mediated
reactions. Currently, the only other treatment for Pompe
disease available in the United States is Myozyme, which
has been in short supply due to limited manufacturing cap-
acity. Both Myozyme and Lumizyme are marketed by Genzyme of
Cambridge, Mass.


Bone marrow: Major role in viral response

NEW YORK - U.S. medical investigators say they have discov-
ered how bone marrow plays a critical role in enhancing a
person's immune response to viruses. Researchers at the
Mount Sinai School of Medicine said their discovery makes
bone marrow a potential therapeutic target, especially in
people with compromised immune systems. They said they found
that during infections of the respiratory tract, cells pro-
duced by the bone marrow are instructed by proteins to mig-
rate to the lungs to help fight infection. The scientists,
led by Assistant Professor Carolina Lopez, evaluated the
immune response to influenza infection in the lungs and blood
of mice. The team found that in the days following infection,
the lung became inflamed and produced interferons, or in-
fection-fighting proteins -- a message that alerted bone
marrow cells of the presence of the virus and signaled them
to prepare to fight the infection. The researchers said they
determined many new cells generated in the bone marrow enter
the infected lung to help fight infection. "Very limited
research has been done to evaluate bone marrow's response
to a virus infection," Lopez said. "Our study is the first
to determine the pivotal role bone marrow cells play in
fighting a respiratory infection. This discovery has broad-
reaching implications in boosting protection against viruses."
The data are published in the current issue of the journal
Cell Host & Microbe.

--------------- Health Tip Video of the Week ---------------

Treatment vs. Addiction - The Fight Against Pain

Rating: 5

Pain varies from person to person and from high amounts to
low amounts; there is no standard measurement. It is some-
times hard to not become addicted to pain treatment medicine.

http://www.evtv1.com/player.aspx?itemnum=14925

Health Related Videos>